Metropolis Healthcare Ltd (NSE: METROPOLIS) just wrapped up Q2FY26 with a clean bill of financial health — ₹429 crore revenue (+23% YoY), ₹108 crore EBITDA (+19% YoY), and ₹53 crore PAT (+13% YoY). The operating margin stands at a healthy 25%, proving that pathology can be profitable if you know your samples (and your investors). The company declared an interim dividend of ₹4 per share, because what’s a good quarter without a little vitamin D(ividend)?
With a market cap of ₹10,524 crore and a stock price of ₹2,031 (P/E 66.5x), the diagnostics diva is trading at 7.34x its book value — pricier than a Mumbai full-body check-up package. Despite that, it’s showing a respectable ROE of 11.5% and ROCE of 14.7%, meaning its blood pressure is stable and pulse promising.
Quarterly sales jumped 22.7% YoY, while profit grew 13.2%. For a business where you make money diagnosing other people’s problems, Metropolis seems to be managing its own quite well.
2. Introduction – When Your Balance Sheet Looks Healthier Than Most Patients
Metropolis Healthcare is the second-largest diagnostic player in India — but it doesn’t just prick needles and print reports. It’s a pathology empire. Headquartered in Mumbai, it runs a lab and collection network so vast that even Google Maps gives up midway.
Founded and chaired by Dr. Sushil Shah and currently helmed by his daughter, Ameera Shah, Metropolis has become synonymous with premium diagnostic services across India and emerging markets. While competitors like Dr. Lal PathLabs and Vijaya Diagnostics often fight for “who’s cheaper,” Metropolis markets itself as the “luxury blood test experience.” They call it “Premium Wellness,” we call it “when your cholesterol report comes with an existential crisis.”
In H1FY24 alone, Metropolis clocked 5.8 million patient visits and performed 11.6 million tests — that’s more tests than Tinder matches in Mumbai during monsoon. The average revenue per test stands at ₹494, showing they’re not running a discount pathology, but a premium boutique of biochemistry.
The company is now present across 488 towns and boasts 3,854 service touchpoints and 167 labs, with ambitions to add 90 more labs and 1,800 service centers by FY25. Clearly, this isn’t a blood test chain anymore; it’s a diagnostic empire on a national conquest.
3. Business Model – WTF Do They Even Do?
Metropolis’ business model is as clinical as its labs. They make money by analyzing other people’s health data — and charging handsomely for it. The company operates through a hub-and-spoke structure: central reference labs handle complex tests, while smaller satellite labs and collection centers feed them samples.
Their business mix is dominated by the Core Testing Business (98%), which includes high-tech and specialized diagnostics. COVID testing, which once contributed big bucks, has now shrunk to just 1.5%, while PPP contracts (Public-Private Partnerships) contribute a mere 0.5% — meaning the real business comes from corporate, B2B, and individual testing.
About 51% of its revenue still comes from the B2B segment, i.e., hospitals, smaller labs, and corporate clients. While this brings volumes, it also means longer receivable cycles. It’s the diagnostic industry’s version of “yeh paisa kab aayega?”
But what makes Metropolis different is its asset-light model — over 92% of its central labs and 18% of its network run on leased setups. That’s corporate-speak for “We don’t buy buildings; we just rent microscopes.”
And just when you thought they were done expanding, the company started aggressively acquiring local labs — including Dr. Ahujas’ Pathology (May 2025), Scientific Pathology (Mar 2025), and Ambika Pathology (Sep 2025) — effectively stitching together India’s local champions into one mega-brand.
4. Financials Overview – When Numbers Don’t Lie (They Just Need Calibration)
Metric (₹ Cr)
Q2FY26 (Latest)
Q2FY25 (YoY)
Q1FY26 (QoQ)
YoY %
QoQ %
Revenue
429
350
386
22.7%
11.1%
EBITDA
108
90
90
20.0%
20.0%
PAT
53
47
45
13.2%
17.8%
EPS (₹)
10.17
9.08
8.70
12.0%
17.0%
Annualized EPS: ₹40.7 → P/E ≈ 50x on annualized basis (CMP ₹2,031). Verdict: “P/E not meaningful” would apply if profits were negative. But here, they’re just “medically expensive.”
Commentary: Metropolis’ financials look as consistent as a good lab report — revenue up, margins steady, PAT growing. However, OPM has slightly declined from the pre-pandemic 28–29% zone to the 25% mark — partly due to higher employee costs and acquisitions. Still, compared to Thyrocare or Krsnaa Diagnostics, the company’s OPM stability is enviable.
5. Valuation Discussion – Fair Value Range (Educational Only)
Let’s apply three diagnostic tests of valuation.
(a) P/E Method
EPS (TTM): ₹30.6 Industry P/E: 43.1x Current P/E: 66.5x
